Seismic Therapeutic vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Seismic Therapeutic raised $222M+ total ($121M Series B in 2023, $25M in 2025) using its IMPACT ML platform; dosed first patient in Phase 1 for S-4321 bifunctional antibody in autoimmune disease.
About
Seismic Therapeutic is a clinical-stage biotechnology company based in Boston, Massachusetts that applies machine learning to the discovery and development of novel immunotherapies for autoimmune diseases. Founded with a focus on precision immunology, Seismic built its IMPACT platform to model the complex biology of adaptive immunity — identifying which immune cell populations drive specific autoimmune conditions and designing biologics that precisely modulate those populations without broadly suppressing the immune system. This targeted approach aims to produce safer, more effective treatments for conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.